Several promising biomarkers like plasma levels of VEGF-A or VEGFR-2 [31, 35, 36], tissue markers like the VEGFR co-receptor neuropilin-1 (NRP-1) [37–39], single nucleotide polymorphisms (SNPs) in VEGF-A [40] or clinical markers like treatment-induced hypertension [40–42] showed convincing results in their early development as treatment predictors. Here, VEGFA is linked to hypertensive disorder.